261 related articles for article (PubMed ID: 21406957)
1. Resistant prolactinomas.
Vasilev V; Daly AF; Vroonen L; Zacharieva S; Beckers A
J Endocrinol Invest; 2011 Apr; 34(4):312-6. PubMed ID: 21406957
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
3. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.
Recouvreux MV; Camilletti MA; Rifkin DB; Díaz-Torga G
J Endocrinol; 2016 Mar; 228(3):R73-83. PubMed ID: 26698564
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
6. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
7. Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D
Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
[TBL] [Abstract][Full Text] [Related]
8. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
9. A case of a prolactinoma resistant to dopamine agonists.
Vourliotaki I; Bonapart IE; Stamataki C; Tsapakis EM; Saridaki C
Hormones (Athens); 2005; 4(3):165-70. PubMed ID: 16613827
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?
Klibanski A
J Clin Endocrinol Metab; 2009 Jul; 94(7):2247-9. PubMed ID: 19584197
[No Abstract] [Full Text] [Related]
11. Activin-inhibitory action on lactotrophs is decreased in lactotroph hyperplasia.
Faraoni EY; Abeledo Machado AI; Pérez PA; Marcial López CA; Camilletti MA; Peña-Zanoni M; Rulli SB; Gutiérrez S; Díaz-Torga G
J Endocrinol; 2020 Feb; 244(2):415-429. PubMed ID: 32395971
[TBL] [Abstract][Full Text] [Related]
12. Giant prolactinomas: Multi-modal approach to achieve tumor control.
Shimon I
Endocrine; 2017 May; 56(2):227-228. PubMed ID: 28050685
[No Abstract] [Full Text] [Related]
13. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.
Biagetti B; Simò R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681905
[TBL] [Abstract][Full Text] [Related]
15. Refractory lactotroph adenomas.
Urwyler SA; Karavitaki N
Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
[TBL] [Abstract][Full Text] [Related]
16. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs.
Cheng J; Xie W; Chen Y; Sun Y; Gong L; Wang H; Li C; Zhang Y
Drug Resist Updat; 2024 Mar; 73():101056. PubMed ID: 38277755
[TBL] [Abstract][Full Text] [Related]
18. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
Musolino NR; Passos VQ
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
[TBL] [Abstract][Full Text] [Related]
19. Pituitary gland: can prolactinomas be cured medically?
Molitch ME
Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
[TBL] [Abstract][Full Text] [Related]
20. Current approach to treatments for prolactinomas.
Tirosh A; Shimon I
Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]